ECOM +19% Reported preliminary revenue and EBITDA, above high range of guidance. Includes estimated net loss.
BPTH +16% Pretty easy fade, a nanocap bio that was coming down in the PM. The trial was a preclinical one, with mice. The results were for treatment of solid tumors. A month ago, this drug had results for a ph 2 trial of leukemia. So same drug for 2 different diseases? Sounds like BS.
AAOI +12% Had come down a lot over the past few months. No apparent news for rally. A whopping 79% of the float is short.
SIEN +8% Up on FDA approval of breast implant supplement.
MYO +8% Up on no news.
CIFS +8% Continued uptrend despite Muddy Waters protests.
CRSP +8% Continued 3 day uptrend off positive data on 4/16.
ENPH +8% Roth ug to $6 from $5.50. Stock had been downtrending recently, did a 3 day uptrend.
TCBI +8% Beat estimates.
ADMS +7% Announced final results from ph3 study of Gocovri. Drug has already been FDA approved.
VRAY +7% Up on news that ViewRay's Linac system is used for the first time by Amsterdam medical center.
ACET -64% Lots of pricing pressures against generics. Company breaking debt covenants. Decreasing revenues, likely a BK situation. Generics will continue to have pricing pressure.
SHOS -34% Down on big loss per share. Fell another 16% the next day.
HMNY -33% Down on huge $150M ATM, and another offering. Fell another 10% the next day.
PIR -21% Earnings guidance negative, when concensus was positive.
LLIT -17% Nanocap Chinese medical device company. Unpredictable, no news.